Richard K. Harrison is currently Vice President of Biomedicine at Aitia. Richard had over 35 years’ experience in pharmaceutical research and consulting. Richard comes to GNS after serving as Chief Scientific Officer at several AI-driven drug discovery companies, including Causaly, PercayAI and Thomson Reuters. Richard’s pharmaceutical research experience spans 30 years working for companies such as Merck, Aventis, and Novartis in all phases of pre-clinical drug discovery from target identification through Phase I. He has worked on scientific teams delivering numerous clinical candidates and several marketed drugs. In addition, Richard was a founding scientist in both a structure based and a computational based drug design company.
Richard holds a Ph. D. in Physical Organic Chemistry from Rutgers University. He has authored over 50 peer-reviewed publications and delivered over 50 invited lectures, serves as reviewer for several journals, and served as an adjunct professor at both Rutgers and Drexel Universities.